FAS REGULATES T CELL DEVELOPMENT/FUNCTION IN LPR MICE
FAS REGULATES T CELL DEVELOPMENT/FUNCTION IN LPR MICE
批准号:
6534048
负责人:
Ralph C Budd
金额:
$28.88万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-09-01 至 2005-05-31
关键词:
CD95 molecule DNA binding protein T cell receptor T lymphocyte apoptosis biological signal transduction cysteine endopeptidases genetically modified animals human subject laboratory mouse lymphocyte proliferation mitogen activated protein kinase nuclear factor kappa beta tissue /cell culture transfection
中文摘要
描述(改编自研究者摘要):本申请
探讨Fas天然抑制剂对免疫功能的影响,
半胱天冬酶-8(FLICE),称为FLIP(FLICE抑制蛋白)。它还提请
过表达FLIP的小鼠和Fas缺陷的lpr小鼠之间的相似之处。的
初步研究结果表明,可溶性Fas配体(FasL)可以共刺激
抗CD 3增殖和IL-2产生的原代T细胞在一个
半胱天冬酶依赖型。T细胞的Fas共刺激也上调ERK
和NF-κ B活性。这可能是通过FLIP介导的物理
FLIP与Raf-1(ERK通路的上游调节因子)的关联,以及
TRAF-1和RIP(与NF-κ B通路连接)。因此,FLIP具有
双重功能,不仅抑制Fas介导的细胞死亡,
在与胱天蛋白酶-8竞争的情况下,它也正性地发出信号以增强TCR信号。
目的1检查是否FLIP裂解的胱天蛋白酶-8实际上是需要的
增加ERK和NF-κ B活性。FLIP含有两种潜在的半胱天冬酶
裂解位点这些已经被突变,突变的FLIP将稳定地
转染到T-和B-细胞系中以及逆转录病毒转染到
原代T细胞不可裂解的FLIP应与内源性FLIP竞争,
在DISC(死亡诱导物信号复合物)处与胱天蛋白酶-8或FADD结合
降低ERK和NF-κ B的激活。目标2研究了
FLIP转基因(Tg)小鼠中CD 8+细胞的耗竭,以及这是否会导致
从FLIP诱导的TCR信号传导增加和选择性过早细胞死亡
CD 8 + T细胞在缺乏Fas的lpr小鼠中则相反
表情将TCR-Tg小鼠OT-1培育成FLIP-Tg和lpr小鼠,
卵清蛋白肽(OVAp)将用于监测ERK和NF-κ B活化,
增殖、体内细胞周期和死亡。目标3检查FLIP是否
过度表达或Fas缺乏导致“误选“保留
胸腺细胞,即在阳性选择中存活但随后不遇到
任何适当的肽/MHC组合在外周,并通常是
通过凋亡消除,但保留在过表达FLIP或
缺少Fas。这种“错误选择的”CD 8 + T细胞可能是免疫缺陷的来源。
在lpr小鼠中积累CD 4 -8-T细胞。目的4研究FLIP水平是否
表达决定哪些T细胞成为记忆T细胞。我们探索一个模型,
该FLIP水平与电池循环的强度成比例地降低,
使快速循环的T细胞对Fas诱导的死亡敏感。但这些
周期较弱的T细胞将维持FLIP水平并存活至
变成记忆T细胞
英文摘要
DESCRIPTION (Adapted from the Investigator's abstract): This application
explores the influence on immune function by the natural inhibitor of Fas and
caspase-8 (FLICE) known as FLIP (FLICE-inhibitory protein). It also draws
parallels between mice over-expressing FLIP and Fas-deficient lpr mice. The
preliminary findings show that soluble Fas-ligand (FasL) can co-stimulate with
anti-CD3 proliferation and IL-2 production by primary T-cells in a
caspase-dependent fashion. Fas co-stimulation of T-cells also up-regulates ERK
and NF-kappaB activities. This is likely mediated by FLIP via the physical
association of FLIP with Raf-1 (the upstream regulator of the ERK pathway), and
TRAF-1 and RIP (which connect with the NF-kappaB pathway). As such FLIP has a
dual function of not only inhibiting Fas-mediated cell death through
competition with caspase-8, it also signals positively to augment TCR signals.
Aim 1 examines whether FLIP cleavage by caspase-8 is actually required for it
to augment ERK and NF-kappaB activities. FLIP contains two potential caspase
cleavage sites. These have been mutated and the mutant FLIP will be stably
transfected into T- and B-cell lines as well as retrovirally transfected into
primary T-cells. The non-cleavable FLIP should compete with endogenous FLIP for
binding to caspase-8 or to FADD at the DISC (Death-Inducer Signaling Complex)
to decrease activation of ERK and NF-kappaB. Aim 2 studies the reason for the
depletion of CD8+ cells in FLIP-transgenic (Tg) mice, and whether this results
from FLIP-induced increased TCR signaling and premature cell death selectively
by CD8+ T-cells. The opposite scenario is considered in lpr mice that lack Fas
expression. The TCR-Tg mouse OT-1 has been bred to FLIP-Tg and lpr mice and
ovalbumin peptide (OVAp) will be used to monitor ERK and NF-kappaB activation,
proliferation, in vivo cell cycling, and death. Aim 3 examines whether FLIP
over-expression or Fas deficiency cause retention of ""misselected""
thymocytes, T-cells that survived positive selection but then do not encounter
any proper peptide/MHC combination in the periphery, and are normally
eliminated by apoptosis, but are retained in mice over-expressing FLIP or
lacking Fas. Such "misselected" CD8+ T-cells may be the source of the
accumulating CD4-8- T-cells in lpr mice. Aim 4 studies whether levels of FLIP
expression determine which T-cells become memory T-cells. We explore a model in
which FLIP levels decrease proportional to the intensity of cell cycling,
making rapidly cycling T-cells sensitive to Fas-induced death. However, those
T-cells which cycle less intensely will maintain FLIP levels and survive to
become memory T-cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vermont Center for Immunobiology/Infectious Diseases (VCIID)
-
批准号:10395160
-
项目类别:
-
资助金额:$30.89万
-
财政年份:2020
-
负责人:Ralph C Budd
-
依托单位:
Pilot Projects
-
批准号:10006840
-
项目类别:
-
资助金额:$44.7万
-
财政年份:2016
-
负责人:Ralph C Budd
-
依托单位:
Metabolic Regulation of Caspases and Survival in T Cells
-
批准号:9110491
-
项目类别:
-
资助金额:$19.3万
-
财政年份:2016
-
负责人:Ralph C Budd
-
依托单位:
VCIID Administrative Core
-
批准号:10006837
-
项目类别:
-
资助金额:$25.69万
-
财政年份:2016
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobiology / Infectious Diseases Center
-
批准号:10006835
-
项目类别:
-
资助金额:$116.48万
-
财政年份:2016
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTER
-
批准号:8360768
-
项目类别:
-
资助金额:$89.31万
-
财政年份:2011
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
-
批准号:8167727
-
项目类别:
-
资助金额:$85.05万
-
财政年份:2010
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
-
批准号:7959813
-
项目类别:
-
资助金额:$93.51万
-
财政年份:2009
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobiology / Infectious Diseases Center
-
批准号:7906346
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2009
-
负责人:Ralph C Budd
-
依托单位:
Gamma Delta T Cells in Lyme Arthritis
-
批准号:7932685
-
项目类别:
-
资助金额:$24.08万
-
财政年份:2009
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobiology / Infectious Diseases Center
-
批准号:7892082
-
项目类别:
-
资助金额:$81.33万
-
财政年份:2009
-
负责人:Ralph C Budd
-
依托单位:
A caspase-8 substrate in T cell activation
-
批准号:7629025
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2008
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
-
批准号:7720912
-
项目类别:
-
资助金额:$104.34万
-
财政年份:2008
-
负责人:Ralph C Budd
-
依托单位:
A caspase-8 substrate in T cell activation
-
批准号:7522455
-
项目类别:
-
资助金额:$22.58万
-
财政年份:2008
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
-
批准号:7610747
-
项目类别:
-
资助金额:$56.03万
-
财政年份:2007
-
负责人:Ralph C Budd
-
依托单位:
ALTERATIONS & RENOVATIONS
-
批准号:7610755
-
项目类别:
-
资助金额:$19.98万
-
财政年份:2007
-
负责人:Ralph C Budd
-
依托单位:
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
-
批准号:7382229
-
项目类别:
-
资助金额:$47.09万
-
财政年份:2006
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobiology / Infectious Diseases Center
-
批准号:7862615
-
项目类别:
-
资助金额:$216.67万
-
财政年份:2006
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobioloigy/ Infectious Diseases Center
-
批准号:8526480
-
项目类别:
-
资助金额:$212.68万
-
财政年份:2006
-
负责人:Ralph C Budd
-
依托单位:
Vermont Immunobioloigy/ Infectious Diseases Center
-
批准号:8711515
-
项目类别:
-
资助金额:$215.95万
-
财政年份:2006
-
负责人:Ralph C Budd
-
依托单位:
海外基金